目的 探討蘇黃止咳膠囊聯合茶堿緩釋片治療哮喘急性發(fā)作的臨床效果。方法 選取2018年8月—2021年8月平煤神馬醫(yī)療集團總醫(yī)院收治的86例哮喘急性發(fā)作患者，運用隨機數字表法分成對照組和治療組，每組各43例。對照組口服茶堿緩釋片，1片/次，2次/d。治療組在對照組基礎上口服蘇黃止咳膠囊，3粒/次，3次/d。兩組患者均治療14 d。觀察兩組臨床療效，比較治療前后兩組患者主要臨床癥狀消失時間，肺通氣功能、哮喘控制測試（ACT）問卷評分和簡易版哮喘生活質量調查問卷（miniAQLQ）評分，呼出氣一氧化氮（FeNO）和血清白細胞介素-33（IL-33）、C反應蛋白（CRP）、血管內皮生長因子（VEGF）水平。結果 治療后，治療組總有效率比對照組顯著提高（95.35%vs 81.40%，P<0.05）。治療后，治療組各項臨床癥狀的消失時間較對照組均顯著縮短（P<0.05）。治療后，兩組第1秒用力呼氣容積百分比（FEV₁%）、呼氣峰流速百分比（PEF%）、ACT問卷評分和miniAQLQ評分均顯著高于治療前（P<0.05），且治療組的改善更顯著（P<0.05）。治療后，兩組FeNO和血清IL-33、CRP、VEGF水平均顯著低于治療前（P<0.05），且治療組降低更顯著（P<0.05）。結論 蘇黃止咳膠囊聯合茶堿緩釋片治療哮喘急性發(fā)作的整體療效滿意，可安全有效地控制哮喘癥狀、改善肺通氣功能及提高生活質量。

Objective To investigate the clinical effect of Suhuang Zhike Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attacks. Methods Patients (86 cases) with acute asthma attacks in General Hospital of Pingmei Shenma Group from August 2018 to August 2021 were divided into control and treatment group by random number table, and each group had 43 cases. Patients in the control group were po administered with Theophylline Sustained-release Tablets, 1 tablet/time, twice daily. Patients in the treatment group were po administered with Suhuang Zhike Capsules on the basis of the control group, 3 grains/time, three times daily. Patients in two groups were treated for 14 d. After treatment, the clinical evaluation was evaluated, the disappearance time of main clinical symptoms, pulmonary ventilation function, ACT questionnaire scores and miniAQLQ scores, FeNO and serum IL-33, CRP, and VEGF levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate of the treatment group was significantly higher than that of the control group (95.35% vs 81.40%, P < 0.05). After treatment, the disappearance time of clinical symptoms in the treatment group was significantly shorter than that in the control group (P < 0.05). After treatment, the scores of FEV₁%, PEF%, ACT questionnaire, and miniAQLQ in two groups were significantly higher than those before treatment (P < 0.05), and the improvement in the treatment group was more significant (P < 0.05). After treatment, the levels of FeNO and serum IL-33, CRP, and VEGF in two groups were significantly lower than those before treatment (P < 0.05), especially in the treatment group (P < 0.05). Conclusion The overall curative effect of Suhuang Zhike Capsules combined with Theophylline Sustained-release Tablets in treatment of acute asthma attacks is satisfactory, which can safely and effectively control asthma symptoms, improve pulmonary ventilation function and improve quality of life.

R974

平頂山市科技計劃項目（2019-152）